Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021		Dec. 31, 2020
Cash flows from operating activities
Net (loss) income	$ (139,805,000)	$ (8,908,000)	[1]	$ 1,983,000	[1]
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Impairment of intangible assets	110,364,000	0		0
Depreciation	6,775,000	4,663,000		2,035,000
Amortization of intangible assets	9,697,000	8,202,000		3,033,000
Amortization of loan costs	18,000	121,000		0
Stock-based compensation	25,334,000	13,956,000		5,981,000
Non-cash lease expense	3,486,000	2,053,000		737,000
Deferred income tax benefit	(5,238,000)	(20,127,000)		(3,297,000)
Change in fair value of contingent consideration	(4,754,000)	2,875,000		1,575,000
Change in fair value of warrant liability	(0)	121,000		(3,601,000)
Change in fair value of investments	(697,000)	0		(1,319,000)
Accretion of investments	(447,000)	0		0
Gain on acquisition of Sexton Biotechnologies, Inc.	0	(6,451,000)		0
Stock issued for services	0	0		60,000
Loss on disposal of assets held for rent, net	773,000	609,000		365,000
Loss on disposal of property and equipment, net	745,000	482,000		0
Forgiveness of loans payable	0	(284,000)		0
Other	166,000	353,000		190,000
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	(10,753,000)	(10,132,000)		(1,786,000)
Inventories	(6,559,000)	114,000		(629,000)
Prepaid expenses and other current assets	26,000	2,663,000		(50,000)
Accounts payable	414,000	2,018,000		(171,000)
Accrued expenses and other current liabilities	1,787,000	(3,936,000)		780,000
Sales taxes payable	1,526,000	1,412,000		759,000
Warranty liability	(1,086,000)	5,833,000		0
Other	(260,000)	(230,000)		0
Net cash used in operating activities	(8,488,000)	(4,593,000)		6,645,000
Cash flows from investing activities
Payments related to the acquisition of SciSafe, net of cash acquired				(14,947,000)
Cash acquired in acquisition of Global Cooling, Inc. and Sexton Biotechnologies, Inc.	0	1,559,000
Purchases of property and equipment	(10,385,000)	(8,385,000)		(1,961,000)
Deposits on property and equipment	0	0		(2,672,000)
Purchases of assets held for rent	(3,536,000)	(6,371,000)		(2,813,000)
Deposits on assets held for rent	0	0		(362,000)
Proceeds from sale of marketable securities	420,000	0		0
Maturities of marketable securities	8,500,000	0		0
Investment in available-for-sale securities	(53,116,000)	0		0
Proceeds from sale of equipment	0	5,000		35,000
Net cash used in investing activities	(58,117,000)	(13,192,000)		(24,715,000)
Cash flows from financing activities
Proceeds from term loan	20,000,000	0		0
Payments on term loan	(1,666,000)	0		0
Payments of contingent consideration	0	0		(483,000)
Fees paid related to issuance of common stock	(131,000)	(145,000)		0
Proceeds from line of credit	0	27,306,000		0
Payments on line of credit	0	(31,536,000)		0
Proceeds from exercise of common stock options	323,000	1,418,000		1,472,000
Proceeds from exercise of warrants	0	0		40,000
Other	(337,000)	(124,000)		(56,000)
Net cash provided by (used in) financing activities	16,316,000	(2,778,000)		102,078,000
Net decrease in cash, cash equivalents, and restricted cash	(50,289,000)	(20,563,000)		84,008,000
Cash, cash equivalents, and restricted cash – beginning of period	69,870,000	90,456,000		6,448,000
Effects of currency translation on cash, cash equivalents, and restricted cash	(108,000)	(23,000)		0
Cash, cash equivalents, and restricted cash – end of period	19,473,000	69,870,000		90,456,000
Non-cash investing and financing activities
Cashless exercise of warrants reclassified from warrant liability to common stock	0	2,901,000		33,111,000
Equipment acquired under operating leases	243,000	6,875,000		8,096,000
Equipment acquired under finance leases	0	440,000		0
Purchase of property and equipment not yet paid	478,000	197,000		0
Unrealized gains and losses on available-for-sale-securities	50,000	0		0
Reclassification of warrant liabilities to equity upon exercise	0	0		110,000
Stock issued as bonus consideration	0	0		314,000
Cash interest paid	586,000	452,000		0
Global Cooling, Inc. and Sexton Biotechnologies [Member]
Non-cash investing and financing activities
Stock issued as consideration	0	264,718,000		0
SciSafe [Member]
Non-cash investing and financing activities
Stock issued as consideration	817,000	0		17,916,000
Common Stock, 2020 [Member]
Cash flows from financing activities
Proceeds from sale of common stock, net of $6.2 million of costs in 2020	0	0		100,121,000
Fees paid related to issuance of common stock				(6,200,000)
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities
Proceeds from loans	0	0		2,175,000
Payments on loans	0	0		(2,175,000)
Equipment Loans [Member]
Cash flows from financing activities
Proceeds from loans	0	1,550,000		984,000
Payments on loans	(498,000)	(214,000)		0
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	(1,375,000)	(1,033,000)		0
IVexSol Preferred Stock Investment [Member]
Cash flows from investing activities
Investment	0	0		(1,000,000)
PanTHERA Cryosolutions Investment [Member]
Cash flows from investing activities
Investment	$ 0	$ 0		$ (995,000)

[1] The Consolidated Statements of Comprehensive (Loss) Income for the years ended December 31, 2021 and 2020 were adjusted by the impact to net (loss) income noted here. Comprehensive loss for the year ended December 31, 2021 is now reported at $9.2 million, reflecting an adjustment of $1.3 million, and was previously reported as $7.9 million. Comprehensive income for the year ended December 31, 2020 is now reported at $1.9 million, reflecting an adjustment of negative $684,000, and was previously reported as $2.7 million.